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Available online 24 September 2013There is a major unmet medical need for treatment options in elderly patients with acute
myeloid leukemia (AML) who are deemed ineligible for intensive treatment. The recent
approval of decitabine in the European Union for the treatment of patients with
AML ≥ 65 years old highlights the potential for hypomethylating agents in this setting.
Here, we review evidence to support the use of hypomethylating agents in elderly patients
and emphasize the importance of tolerability and quality of life considerations. We focus on
the rationale for the continued clinical development of the ribonucleoside analog
azacitidine in this setting. We discuss potential differences in the activity of azacitidine
and decitabine in different patient subgroups that could possibly be explained by important
differences in mechanism of action. Finally, we assess practical challenges that will be
faced when integrating hypomethylating agents into clinical practice, such as how to define
ineligibility for intensive treatment.
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Acute myeloid leukemia (AML) is mostly a disease of the
elderly with a median age at diagnosis of ~70 years.1 Older
patients with AML have significant comorbidities, a poorer
performance status (PS), more unfavorable cytogenetic abnor-
malities, and a higher incidence of secondary AML than their
younger counterparts.1
The decision whether to allocate intensive or non-intensive
treatment options to elderly patients with AML (>60 years old)
is both challenging and complex and requires careful assess-
ment of disease- and patient-related factors. In some elderly
patients, intensive chemotherapy (IC) is an acceptable standard
of care, leading to a 45–55% response rate with the potential of
improving prognosis.2–5 However, long-term survival generally
remains low due to a higher risk of relapse and treatment-
related mortality compared with younger patients.6 Patients
deemed ‘unfit’ or ineligible for IC are frequently offered best
supportive care (BSC) only. Unfortunately, prognosis in
untreated elderly patients is dismal. In a Surveillance, Epide-
miology, and End Results cancer registry analysis, median
survival in 2657 adults ≥65 years was 2 months and the 2-year
survival rate was 6%. For untreated patients, median survival
was 1 month compared to 7 months for the 30%of patientswho
received chemotherapy.7 Alternatively, some frail patients are
offered low-dose cytarabine (LDAC). Although more tolerable
than IC, outcomes with LDAC are generally poor with a median
survival time of only 4 months.8 Therefore, there is an unmet
need for well tolerated treatment options for these patients.
Hypomethylating agents (HMA) may have the potential to
improve survival and quality of life in elderly patients with
AML. Indeed, quality of life and patient-reported outcomes are
key considerations when selecting appropriate treatment for
the elderly.9
There is biological rationale for assessing HMA in these
patients. Recent studies have demonstrated that gene hyperme-
thylation is widespread in patients with AML and is implicated
in the pathogenesis and progression of the disease.10 Moreover,
extensive clinical experience with two HMA, azacitidine and
decitabine, has demonstrated that the drugs arewell tolerated in
elderly and frail patients.11–14In this review, we discuss available efficacy and safety data
for both azacitidine and decitabine in patients with AML, as
well as current understanding of the mechanism of action of
these drugs. Furthermore, we assess the challenges that will
be faced when integrating HMA into clinical practice, such as
how to define ineligibility for IC.2. Hypomethylating Agents in Elderly Patients
with AML: Phase III Studies
Bothdecitabine andazacitidinehave been, or are being, assessed
in phase III studies in elderly patients with AML (DACO-016 and
AZA-AML-001 trials, respectively).
2.1. DACO-016 Study
The recently published DACO-016 study compared the efficacy
and safety of decitabine (20 mg/m2/day for 5 days every
4 weeks) versus treatment choice (TC; LDAC [20 mg/m2/day for
10 days every 4 weeks] or BSC) in 485 patients who were
deemed ineligible for IC.15 The primary endpoint was overall
survival (OS); secondary endpoints included complete remission
(CR) rate and adverse events (AEs). The median age of patients
enrolled onto the DACO-016 trial was 73 years; 35% of patients
had secondary AML, 36% had poor-risk cytogenetics and 24%
had an Eastern Cooperative Oncology Group (ECOG) PS of 2.
Thepreplannedprimary efficacy analysiswas undertaken in
October 2009 following 396 deaths (Fig. 1). This analysis
demonstrated a non-significant trend towards improved OS in
the decitabine arm versus TC (7.7 vs 5.0 months; p = 0.108). A
year after the initial analysis, an unplanned ad hoc efficacy
analysis was performed following 446 deaths. The median OS
for both arms was the same as in the initial analysis, but the
difference between thedecitabine armand theTC armwas now
nominally significant (p = 0.037; Fig. 1).15 Following adjustment
for study drug exposure, the overall death rate (per patient year)
was lower for decitabine than for LDAC (0.57 vs 0.73). Based on a
subanalysis of the trial, decitabine has not shown any evidence
of improvingOS inpatientswith 20–30%blasts. Incidence ofAEs
was similar between arms. The most common grades 3–4
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Fig. 1 – Predesignated and ad-hoc analyses of overall survival in the DACO-016 trial. 15
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Drug-related AEs occurred in 74% of patients treated with
decitabine and 73% of patients treatedwith LDACwith themost
common being thrombocytopenia (27%), anemia (21%), neutro-
penia (24%) and febrile neutropenia (21%).
Decitabine was recently approved by the European Medi-
cines Agency (EMA) for the treatment of AML in patients aged
≥65 years with de novo/secondary AMLwho are not candidates
for IC.16 In contrast, the US Food and Drug Agency (FDA)
Oncologic Drugs Advisory Committee (ODAC) did not recom-
mend approval of decitabine based on concerns regarding the
statistical validity and robustness of the data. Several issues
including the interpretation of the data of the TC armof the trial
were raised. For example, patients who received BSC, although
few in number (n = 28), were grouped together with patients
treated with LDAC when TC was compared to decitabine. The
negative impact of this fact on OS in the TC arm could not be
excluded. The FDA ODAC highlighted a number of concerns
regarding the results of DACO-016 which, in their view,
precluded marketing approval: i) a lower than expected
response rate in the LDAC arm; ii) inexplicable variation in
efficacy across different geographical regions; in Western
Europe, for example, the CR rate with LDAC was higher than
the response rate with decitabine. iii) unplanned and explor-
atory ad hoc analysis of OS; iv) failure to achieve primary
endpoint. Additionally, concerns regarding the lack of strict
criteria for entry to the study were expressed. About 10% of
patients who supposedly were deemed not to be fit for IC
ultimately received IC following randomization in the study.
This may encourage some physicians to use decitabine in
patients who may be better candidates for IC.9,17
2.2. AZA-AML-001 Study
In the ongoing AZA-AML-001 trial, patients (target enrolment of
480 patients) were randomized 1:1 to receive either azacitidine
(75 mg/m2/day for 7 days every 4 weeks) or conventional care
regimen (CCR; BSC, LDAC [40 mg/day for 10 days every 4 weeks]or IC). Choice of CCR was assigned by the treating physician.
The primary endpoint of AZA-AML-001 is OS. Secondary
endpoints include remission rate, event-free survival, safety
and, importantly, patient-reported quality of life outcomes.
Inclusion criteria for AZA-AML-001 were similar to DACO-016,
although there were some notable differences. Firstly, patients
in the control arm of AZA-AML-001 could receive IC, LDAC or
BSC rather than just LDAC or BSC. Secondly, a bone marrow
(BM) blast count of >30%, rather than ≥20%, was required.
The AZA-AML-001 trial is scheduled to be completed
(including final data collection for primary outcome measure)
late 2013. These data will be instrumental in defining the
future role of azacitidine in patients with AML and >30%
blasts. Azacitidine is already approved for the treatment of
patients with AML and 20–30% blasts, based on a subanalysis
of the phase III AZA-001 trial (described below).11
2.3. AZA-001 Study
TheAZA-001 trial compared theefficacy and safety of azacitidine
with CCR (BSC, LDAC, IC) in 358 patients with predominantly
int-2-/high-risk MDS.18 However, 113 patients with WHO-AML
(20–30% blasts) were also included.11 The efficacy population
included 55 patients randomly assigned to azacitidine and 58
patients randomly assigned to CCR. Of the 58 patients in the CCR
group, 27 (47%), 20 (34%), and 11 (19%) were preselected by their
treating physicians to receive BSC, LDAC, and IC, respectively.
Baseline characteristics were comparable between the two
treatment groups. In these patients: i) azacitidine halved the
risk of death compared with CCR. After a median follow-up of
20.1 months, OS was 24.5 months in the azacitidine group and
16.0 months in the CCR group (HR [95%CI] = 0.47 [0.28–0.79]; p =
0.005; Fig. 2); further, a survival comparison between azacitidine
vs CCR according to investigator pre-selection was conducted. A
significant difference in OS favoring azacitidine (n = 36) vs BSC
(n = 27), with median OS of 19.1 vs 13.4 months, respectively
(p = 0.03) was detected. Median OS for azacitidine (n = 14) was
24.5 vs 17 months for LDAC (n = 20) (p = 0.08). Median OS was
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Fig. 2 – AZA-001: Overall survival in WHO-defined patients
with AML (20–30% blasts). 11
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for IC (n = 11) (p = 0.97). Although interesting, the data must be
interpretedwith cautionbecause of the small number of patients
in each CCR regimen. ii) Significantly more patients who were
red blood cell transfusion-dependent (RBC-TD) at baseline
achieved transfusion independence with azacitidine compared
with CCR (41% vs 18%, respectively; p = 0.04); iii) AEs were
generally predictable (predominantly hematological, gastroin-
testinal or injection site reactions) and manageable on treat-
ment; iv) the CR rate in the azacitidine arm was 18% compared
with 16% in theCCR arm, indicating that CR is not a prerequisite
for survival benefit in patients treated with azacitidine.
Based on this analysis, azacitidine has become established
as a treatment option in patients with WHO-AML (20–30%
blasts) who are ineligible for intensive treatment.3. Hypomethylating Agents in Elderly Patients
with AML: Phase II Studies
To date, there are no prospective data available that directly
compare the efficacy and safety of azacitidine and decitabine in
patients with AML. To date, three phase II studies have been
reported for decitabine in patients with AML (all first-line elderly
patients deemed ineligible for IC; Table 1). 19–21 One phase II study
of azacitidine monotherapy in patients with AML (in both
first-line and relapsed/refractory patients) has been published.22
Our study assessed the efficacy and safety of azacitidine
(75 mg/m2/day for 5 days every 28 days) in patients with AML
and ≥20% BM blasts who were deemed medically unfit for IC,
based on comorbidity profile. 22 The study demonstrated that
azacitidine was generally well tolerated; all treatment-related
AEs were reversible and effectively managed with supportive
measures and dose delays. Median OS in patients treated with
first-line azacitidine (7.7 months) compared favorably with OS
rates historically achieved with LDAC (median survival of
4 months).8 Median OS in patients who achieved stable disease
(SD) was 10 months, which was similar to that achieved in
patients with CR, partial response (PR) or hematological
improvement (HI). Again, these data suggest that CR is not a
prerequisite for improved survival in patients with AML given
azacitidine, as is also the case in patients with MDS and
WHO-AML (20–30% blasts).11,18 The response rate in patientswith previously untreated AML was 50%. There was also some
evidence of clinical activity in patients with relapsed/refractory
AML (response rate of 10%). An important observation was that
hematological responses were rapid (median time to response
was 2.5 months); furthermore, early reductions in BM blast
count by day 15 of the first cycle were highly predictive of
subsequent response.22 This suggests that azacitidine elicits
early anti-leukemia responses, which is clearly an important
consideration when treating patients with high-risk disease
and very dismal prognosis.
Based on the three published phase II decitabine studies
(Table 1) survival with azacitidine seems comparable with that
observed in decitabine trialswhich reportedmedianOS ranging
from5.5 months to~1 year and 1-yearOS of ~30–50%.However,
it is not possible to come to any definitive conclusions regarding
the relative efficacy and safety of the two drugs based on these
small phase II studies.4. Hypomethylating Agents in Elderly Patients
with AML: Retrospective Studies
A number of retrospective single-center studies or national/
international patient registries have assessed HMA in patients
with AML (Tables 2, 3). The majority of these studies reported
outcomes in patients treated with azacitidine (Table 2) and
are the focus of the following discussion.
Most studies demonstrated that response to azacitidine
was strongly associated with prolonged OS.23,24 Furthermore,
as in the phase II trial, any kind of response to azacitidine
appeared to be sufficient to confer a survival advantage. For
example, in a study of 128 patients treated with azacitidine,
Pleyer et al. demonstrated that achievement of any kind of HI
was associated with longer OS than that observed in patients
who did not achieve HI (18.9 vs 6.0 months; p < 0.001).25
Given the heterogeneity of AML, retrospective studies of large
cohorts of patients may be invaluable for generating hypotheses
regarding the appropriate patient population to be treated with
HMA. It is important to note that the retrospective studies listed
inTables 2 and 3 encompassedawide rangeofAMLpatientswith
diverse risk factor profiles. For example, in patients treated with
azacitidine, the following characteristics ranged from: ECOG PS
≥2: 0–67%; secondary AML: 20–51%; poor-risk cytogenetics:
18–55%; median BM blast count: 34–70%. Clearly, many patients
included in the retrospective studies had high-risk disease. The
impacts of specific disease- andpatient-related characteristics on
clinical outcome in AML patients treated with azacitidine are
discussed below.5. Impact of Patient-Related Factors on
Treatment Choice in Elderly Patients with AML
5.1. Age
Increased age is a negative prognostic factor in patients with
AML but should not be considered in isolation. PS and
comorbidities must also be considered when deciding treat-
ment. 3 Importantly, in several retrospective studies, age per se
did not predict OS in AML patients treatedwith azacitidine. 25,26
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old, which reflects the typical AML population. Similarly, the
medianage in theDACO-016 trialwas 73 years.15Most patients in
this age range would be deemed ineligible for IC. Furthermore,
even in those patients deemed eligible, IC will only benefit
approximately a third of those who receive it.27 These observa-
tions, in addition to disappointing OS in elderly patients treated
with LDAC,8 indicate that HMA could become a promising future
treatment option in very elderly patients.
5.2. Comorbidities
Comorbidities are highly prevalent in elderly patients and
influence treatment decisions.28 In AML management, the
impact of comorbidities is poorly defined and often complicates
treatment decisions. While many comorbidity indices have
emerged in oncology, none have been validated on a large scale
in the management of elderly patients with AML. Comorbidity
scoring could be helpful in identifying subgroups of elderly
patients who are likely to tolerate or benefit from IC.29 It is
encouraging to note that azacitidine appears to be active in
elderly patients regardless of comorbidity burden. Pleyer et al.
demonstrated that the absolute number of comorbidities had no
effect on OS. Furthermore, OS in patients according to low-,
intermediate- and high-risk comorbidity scores (based on hema-
topoietic cell transplantation comorbidity index)was 10.2, 9.0 and
9.7 months, respectively.25 These data suggest that the presence
of comorbidities should not lead to a decision to withhold
treatmentwithHMA in favor of BSC in elderly patientswith AML.
5.3. Performance Status
Performance status (PS) is a frequently used parameter to
quantify a patient's activities of daily life, and determine
whether the patient is eligible for IC. Patients with PS >2 are
often excluded from clinical trials in which patients are to be
treated with IC; according to ECOG, it is generally plausible to
include patients up to 75 years old with no comorbidities and
a PS of 0–1 in such trials.30 HMA might be an option for
patients with poor PS. As expected, most studies demon-
strated that elevated ECOG-PS was associated with poorer OS
in patients treated with azacitidine.25,31 Importantly, howev-
er, the AZA-AML-001 trial will be stratified according to
ECOG-PS and this will determine whether azacitidine offers a
survival advantage over conventional treatment options in
patients with high ECOG-PS. In the DACO-016 trial, the
subgroup of patients with an ECOG-PS of 2, but not 0–1, had
significantly improved survival when treated with decitabine
versus TC.156. Impact of Disease-Related Factors on
Treatment Choice in Elderly Patients with AML
6.1. Cytogenetics
Adverse cytogenetics are associated with poor response rates
and shorter survival in patients treated with IC 32–35 and
LDAC.8With HMA, survival is also superior in patients with
intermediate- compared to high-risk cytogenetics.15,25,26 Nev-
ertheless, in patients with unfavorable cytogenetics included
in the AZA-001 trial, median OS was 12.3 and 5.3 months,
respectively, in the azacitidine and CCR arms (p = 0.38). The
2-year OS rate was 38% and 16%, respectively (p = 0.001).11
In the DACO-016 trial, the survival data were in favor of
decitabine compared with TC for patients with poor-risk
cytogenetics. 15
6.2. ‘Proliferative’ AML
Based on available data it remains unclear whether HMA
could potentially be effective in highly proliferative AML.
Patients with a white blood cell (WBC) count of ≥15 × 109/L
were excluded from AZA-AML-001. In contrast, patients with
a WBC count of ≤40 × 109/L were eligible for DACO-016,
although the median WBC count of enrolled patients was
3.4 × 109/L (range: 0.3–127.0);15 only 24% of patients had a
WBC count of ≥10 × 109/L. Some retrospective studies have
suggested that patients with a WBC count of ≥10 × 109/L
benefit less from azacitidine than those with lower WBC
counts.36 Conversely, other studies have found that WBC
count did not impact OS in patients with AML treated with
azacitidine.25,26
Furthermore, it is unclear whether a given BM blast
threshold has any clinical significance. For example, in
several studies, the OS of patients treated with IC was not
significantly different in patients with 20–30% blasts com-
pared with patients with >30% blasts.37–39 Likewise, some
emerging clinical trial data suggest that HMA are effective in
patients with >30% blasts. In DACO-016, decitabine improved
survival in patients with >30% blasts.15 Except one study,31
retrospective data have indicated that blast count (>30% vs
≤30%) at baseline did not predict OS in elderly patients treated
with azacitidine.25,36
6.3. Type of AML
Incidence of secondary AML from an antecedent hematolog-
ical disorder (AHD) or previous exposure to chemotherapy
and/or radiation (therapy-related AML), increases with age
and is associated with poor outcomes irrespective of age,
cytogenetic risk, PS or whether patients receive IC. Even for
patients <65 years old treated with IC, median OS is only
7–9 months.40 It is clear, therefore, that there is an unmet
clinical need for new treatment options in secondary AML.
Possibilities include HMA and allogeneic hematopoietic stem
cell transplantation using reduced-intensity conditioning
(HCT-RIC).
Few data are available regarding the efficacy of HMA in
secondary AML. In the DACO-016 trial, 36% of enrolled
patients suffered from secondary AML. There was a trend
towards improved survival in patients given decitabine versus
TC which did not achieve statistical significance.15 In
azacitidine studies, 20–51% of patients had secondary AML
(Table 2). A recent retrospective study of 26 patients with AML
secondary to Philadelphia-negative myeloproliferative neo-
plasms indicated that azacitidine was associated with a
promising response rate of 38% and an OS of 8 months.41
Table 1 – Summary of phase II trials of decitabine and azacitidine in patients with AML.
Study Inclusion criteria Baseline characteristics Treatment Response Survival Safety
Lubbert et al.21 • First-line patients
• >60 years old
• ECOG PS: 0–2
• >30% blasts
• Any cytogenetics
• Patients, n: 227
• Median age, years (range):
72 (56–86)
• ECOG PS, 0/1/2, %: 19/58/22
• HCT-CI, 0/1–2/>3, %: 21/42/
37
• AML type, p/s: 49/51
• Median WBC, ×109/L
(range): 4.4 (<1–241)
• Median blasts,%: 56
(10–100)
• Decitabine 135 mg/m2
total dose every 6 weeks
• ATRA given to 100 patients
during cycle 2
• Median cycles, n (range): 2
(1–4)
• ORR: 52%
• CR: 13%
• PR: 13%
• HI: 26%
• Median OS, months: 5.5
• 1 year OS, % (95% CI): 28
(22–34)
• Parameters associated
with worse outcome: low
platelets, age, ECOG-PS
and high LDH
• Grade 3–4 neutropenia,
%: 51
• Grade 3–4 thrombocyto-
penia, %: 51
Cashen et al.20 • First-line patients
• >60 years old
• Int/poor cytogenetics
• ECOG PS: 0–2
• Ineligible for IC or HCT
• >20% blasts
• Patients, n: 55
• Median age, years (range):
74 (61–87)
• ECOG PS, 0/1/2: 47/35/18
• Cytogenetics, int/poor/na:
53/45/2
• AML type, p/s/t: 55/35/7
• Median WBC, ×109/L: 2.7
(1–111)
• Median blasts,%: 50
(0–99)
• Decitabine 20 mg/m2 for
5 days every 4 weeks
• Median cycles: 3 (1–25)
• ORR: 25%
• CR: 24%
• CRi: 2%
• SD: 29%
• Failure: 31%
• n/a: 15%
• Median time to response,
days: 126 (4.5 cycles)
• Minimum follow up:
1 year
• Median OS, months (95%
CI): 7.7 (5.7–11.6)
• Median EFS, months
(range): 5.8 (3 days to
23.6 months)
• Median OS in responders,
months: 14
• Factors that predicted
short survival: ECOG PS
of 2, male gender, high
blasts
• Grade 3–4 neutropenia,
%: 20
• Grade 3–4 febrile neutro-
penia, %: 29
• Grade 3–4 thrombocyto-
penia, %: 22
• Delayed cycles, %: 27
• Dose reductions:
uncommon
Blum et al.19 • First-line patients
• ≥60 years old
• Ineligible or refused IC
• WBC <40 × 109/L
• Patients, n: 53
• Median age, years (range):
74 (60–85)
• MRC prognostic score,
good/standard/poor: 19/
32/49
• Cytogenetics, normal/
complex/other: 40/30/26
• AML type, p/s/t: 64/25/11
• Median WBC, ×109/L
(range): 2.7 (0.4–150)
• Median blasts,% (range): 52
(20–92)
• Decitabine 20 mg/m2 for
10 days every 4 weeks
(dose subsequently
reduced if blasts <5% or
if grade 4 neutropenia
experienced)
• Median cycles, n (range): 4
(1–21+)
• ORR: 64%
• CR: 47%
• CRi: 17%
• CR in patients with WBC
≥15 × 109/L: 57%
• CRs occurred in all cytoge-
netic subgroups
• Median OS, weeks (95% CI):
55 (36–72)
• Median DFS, weeks (95%
CI): 46 (30–NR)
• Four patients received
non-myeloablative HCT
after CR
• Grade 3–4 febrile neutro-
penia, %: 68
(during first two cycles)
94
J
O
U
R
N
A
L
O
F
G
E
R
I
A
T
R
I
C
O
N
C
O
L
O
G
Y
5
(
2
0
1
4
)
8
9
–
1
0
5
Study
Inclusion
criteria
Baseline characteristics Treatment Response Survival Safety
Al-Ali et al.
(first-line)22
• ≥18 years old
• Ineligible or refused IC
• ≥20% BM blasts
• Medically unfit for induc-
tion chemotherapy
• Patients either had serious
comorbidity, or severe
uncontrolled infections
• Patients, n: 20
• Median age, years (range):
78 (64–84)
• Cytogenetic risk, int/high,
%: 75/25
• AML type, p/s, %: 40/60
• Median WBC, ×109/L
(range): 3.4 (0.8–187)
• Median blasts, % (range):
44 (10–90)
• Azacitidine 75 mg/m2 for
5 days every 4 weeks
until progressive disease
or relapse
• Median cycles, n: 6
• ORR: 50%
• SD: 25%
• PD: 0%
• Early death: 25%
• Median time to response,
months (range): 3.5 (2–7)
• Median duration of re-
sponse; months (range):
5.5 (1–NR)
• Median follow-up, months
(range): 13 (9–16)
• Median OS, months
(range): 7.7 (0.2–NR)
• OS similar between pAML
and sAML
• OS in responding patients:
not reached
• OS in patients with SD,
months: 10
• 1 year OS, %: 39
• Grade 3/4 thrombocyto-
penia,%: ~70
• Grade 3/4 neutropenia,
%: ~65
• Hematological AEs were
reversible in all patients,
mainly by dose delays
• Delayed cycles, %: 11
• Patients requiring dose
reduction, %: 13
• Non-hematological AEs
were generally mild and
manageable
Al-Ali et al.
(second-line)22
• Same as above • Patients, n: 20
• Median age, years (range):
67 (32–83)
• Cytogenetic risk, int/high,
%: 65/35
• AML type, p/s/NA, %: 70/
25/5
• Median WBC, ×109/L: 3.6
(0.7–36)
• Median blasts, %: 40
(15–80)
• Relapsed/refractory,%: 65/
35
• As above, except median
cycles, n: 2
• ORR: 10%
• SD: 50%
• PD: 10%
• Early death: 30%
• Median time to response,
months (range): 1.5 (1–2)
• Median duration of re-
sponse; months (range):
4.5 (4–5)
• Median follow-up, months
(range): 13 (9–16)
• Median OS, months
(range): 2.9 (0.7–NR)
• OS similar between refrac-
tory and relapsed
patients
• Grade 3/4 thrombocyto-
penia,%: ~70
• Grade 3/4 neutropenia,
%: ~65
• Hematological AEs were
reversible in all patients,
mainly by dose delays
• Delayed cycles, %: 11
• Patients requiring dose
reduction, %: 13
• Non-hematological AEs
were generally mild and
manageable
ATRA: all-trans retinoic acid, CR: complete response, EFS: event free survival, HI: hematological improvement, LDH: lactate dehydrogenase, n/a: not available, NR: not reported, mCR: complete marrow
response, ORR: overall response rate, OS: overall survival, p: primary, PD: progressive disease, PR: partial response, s: secondary, and t: therapy-related.
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Table 2 – Overview of retrospective studies of azacitidine in patients with AML.
Study Baseline characteristics Treatment Response Survival
a) Patients with previously untreated AML
Bories
et al.26
• Patients, n: 98
• Median age, years (range):
76 (60–89)
• ECOG PS, ≥2, %: 29
• AML type, p/s: 72/28
• WBC, >10 × 109/L, %: 14
• Median blasts,% (range):35
• (0–99)
• Cytogenetics, int/poor, %:
49/45
• Azacitidine 75 mg/m2/day for
7 days every 28 days
• Median cycles, n (range): 6 (1–27)
• ORR: 51%
• CR: 13%
• CRi: 5%
• PR: 6%
• HI: 27%
• Median cycles to best re-
sponse, n: 6
• Median OS, months: ~12
• 1 year OS, %: 50
• Parameters associated with worse OS (multivariate): high LDH, adverse cytogenetics
• Parameters with no effect on OS (multivariate): age, ECOG PS, WBC
Serrano
et al.23
• Patients, n: 67
• Median age, years (range):
71 (60–84)
• ECOG PS, ≥2, %: 67
• Cytogenetics, int/poor, %:
69/22
• AML type, p/s, %: 49/51
• Median WBC, ×109/L
(range): 4.4 (0.2–18)
• Median blasts,% (range): 34
(20–84)
• Azacitidine 75–100 mg/m2 for
7 days every 4 weeks
• Median cycles, n (range): 6 (1–24)
• ORR: 38%
• CR: 13%
• PR: 13%
• HI: 16%
• Median follow up, months (range): 7.4 (1–28.3)
• Median OS, months: 13.7
• OS was significantly higher in patients who responded than patients who did not
respond
• OS was significantly higher in patients with HI than patients who did not respond
Sudan
et al.24
• Patients, n: 20
• Mean age, years (range): 68
(44–80)
• Cytogenetics, normal/sim-
ple/complex, %: 35/25/40
• ECOG ≤1, %: 100
• Median WBC, ×109/L
(range): 4.0 (0.65–105)
• Blasts, ≥30%, %: 40
• Azacitidine 75 mg/m2/day for
7 days every 4 weeks
• ORR: 60%
• CR: 20%
• PR: 25%
• HI: 15%
• Median time to response,
months (range): 3 (2–5)
• RBC-TI: 61%
• Median survival in responders, months (range): 15+ (10–36+)
• Median survival in non-responders, months: 2.5
• No significant difference in OS between patients who achieved CR/PR and those who
achieved HI
Maurillo
et al.36
• Patients, n: 35
• Median age, years (range):
77 (46–87)
• Cytogenetics, int/poor/fail,
%: 37/23/40
• AML type, p/s/t, %: 77/20/3
• Median WBC, ×109/L
(range): 4.0 (0.65–105)
• Median blasts,% (range): 35
(20–80)
• Azacitidine 75 mg/m2/day for
7 days every 4 weeks: 66%
• Azacitidine 100 mg/day for 7 days
every 4 weeks: 34%
• Median cycles, n (range): 6 (1–18)
• ORR: 48%
• CR: 23%
• CRi: 8%
• PR: 17%
• SD: 23%
• Median duration of re-
sponse, months: 6
• Median follow up, months: 12
• Median OS, months: 9
• 1 year OS, %: 35
• Median OS in responders, months: 13
• Median OS in non-responders, months: 5
• Elevated WBC count (>109/L) was associated with poor survival (4 vs 9 months; p =
0.011)
• No significant difference in OS in patients with <30 and ≥30% blasts
Ramos
et al.31
• Patients, n: 110
• Median age, years
(range):75 (56–89)
• Cytogenetics, favorable/int/
adverse, %: 1/58/27
• Median dose: 73.6 mg/m2/day
• 7-day schedule: 64%
• Median cycles, n (range):4(1–29)
• Median follow-up, months:
8.6
• ORR: 45%
• CR: 16%
• Median OS, months: 8.1
• 1 year OS, %: 37
• OS was significantly higher in patients who responded than patients who did not
respond, in patients with ECOG ≤1 and in patients with BM blasts ≤30%
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Study
Baseline characteristics Treatment Response Survival
• ECOG ≥2, %: 30
• sAML, %: 55
• Comorbidities, %: 87
b) Patients with previously untreated or relapsed/refractory AML
Gavillet
et al.51
• Patients, n: 38
• Median age, years (range):
68 (25–86)
• Cytogenetics, favorable/int/
poor, %: 8/64/29
• AML type, p/s/rr, %: 42/45/
13
• Median WBC, ×109/L
(range): 3.1 (0.6–37)
• Median blasts, % (range): 70
(20–90)
• Baseline or acquired
RBC-TI, %: 58%
• Azacitidine 100 mg/m2/day for
5 days every 4 weeks
• Median cycles, n (range): 6 (3–20)
• ORR: 23%
• CRi: 18%
• PR: 5%
• Median OS in RBC-TI patients, months: 11.1
• 1 year OS in RBC-TI patients, %: 40
• Median OS in RBC-TD patients, months: 5
• 1 year OS in RBC-TD patients, %: 13
• Parameters associated with worse OS (multivariate): RBC-TD
• Parameters with no effect on OS (multivariate): peripheral blasts ≥20%, relapsed/
refractory disease
Pleyer
et al.25
• Patients, n: 155
• Median age, years (range):
73 (33–91)
• Cytogenetics (IPSS), good/
int/poor, %: 59/16/17
• Prior chemotherapy, y/n:
39/61
• AML type, p/s/t, %: 37/48/10
• WBC, >10 × 109/L, %: 21
• Blasts, >30%, %: 63
• ECOG PS >1, %: 26
• Comorbidities, 0-1/2-3/>3,
%: 43/39/18
• Azacitidine 75 mg/m2/day for
7 days every 4 weeks: 57%
• Azacitidine 75 mg/m2/day, 5-2-2
schedule every 4 weeks: 22%
• Azacitidine 75 mg/m2 for 5 days
every 4 weeks: 16%
• Other: 5%
• Median cycles, n (range): 4 (1–24)
• ORR: 45%
• CR: 10%
• mCR: 3%
• PR: 21%
• SD with HI: 3%
• HI only: 9%
• RBC-TI (in patients RBC-TD
at baseline; n = 97): 36%
• Median time to response,
months: 4
• Median OS from initiation of azacitidine, months: 9.8
• Median OS according to
o RBC-TI: 19.3 vs 9.6 months
o HI: 18.9 vs 6.0 months
o CR/SD/PD: 24.7 vs 15.2 vs 2.3 months
• Parameters associated with worse OS (multivariate): no HI, no (any) response to
azacitidine, intermediate or high ‘Itzykson’ prognostic score 94
• Parameters with no effect on OS (multivariate): age, WBC count, BM blasts, number of
comorbidities, prior IC
c) Patients with relapsed/refractory AML
Maurillo
et al.36
• Patients, n: 47
• Median age, years (range):
67 (29–81)
• Cytogenetics, int/poor/fail,
%: 66/21/13
• AML type, p/s/t, %: 60/38/2
• Median WBC, ×109/L
(range): 8.0 (0.60–85)
• Median blasts,% (range): 30
(20–90)
• Azacitidine 75 mg/m2/day for
7 days every 4 weeks: 38%
• Azacitidine 100 mg/day for 7 days
every 4 weeks: 62%
• Median cycles, n (range): 4 (1–22)
• ORR: 19%
• CR: 8%
• CRi: 3%
• PR: 8%
• HI: 6%
• SD: 30%
• Median DOR, months: 5
• Median follow up, months: 12
• Median OS, months: 7
• 1 year OS, %: 18
• Median OS in responders, months: 8
• Median OS in non-responders, months: 7
BM: bone marrow, CR: complete response, CRi: complete response with incomplete blast recovery, DOR: duration of response, ECOG PS: European Cooperative Oncology Group performance status, HI:
hematological improvement, IC: intensive care, IPSS: international prognostic scoring system, LDH: lactate dehydrogenase, mCR: complete marrow response, ORR: overall response rate, OS: overall
survival, p: primary, PD: progressive disease, PR: partial response, RBC-TD: red blood cell transfusion dependence, RBC-TI: red blood cell-transfusion independence, rr: relapsed/refractory, s: secondary,
SD: stable disease, t: therapy-related, and WBC: white blood cells.
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Table 3 – Overview of retrospective studies of decitabine in patients with AML.
Study Baseline
characteristics
Treatment Response Survival
a) Patients with previously untreated AML
Gourdin et al.99 • Patients, n: 32
• Median age, years (range):
74 (52–86)
• ECOG PS, ≥2, %: 31
• Karyotype, unfavorable/int/na,
n: 17/14/1
• Comorbidities, %: 100
• Decitabine 20 mg/m2/day
for 10 days
• Subsequent 5-day cycles
until disease progression
if patients
attained <5% BM blasts
• Median cycles, n (range):
2 (1–4)
• ORR: 31%
• CR: 28%
• PR: 3%
• Median DFS, days (range):
390 (87 + −468+)
• Median OS, days (range):
180 (15–623+)
• 6 month OS, %: 37.5
• 1 year OS, %: 16.5
b) Patients with previously untreated or relapsed/refractory AML
Ganetsky et al.52 • Patients, n: 60
• Median age, years (range):
62 (28–80)
• Prior chemotherapy, y/n,
%: 78/22
• Of patients who received
prior chemotherapy:
• Mean chemotherapy
regimens: 2.5
• Post HCT: 30%
• Decitabine 20 mg/m2/day
for 5 days
Overall
• ORR: 13%
• CR: 12%
• PR: 2%
• Mean cycles to achieve
maximal response,
n: 3.25
Relapsed/refractory
AML
• CR: 8.5%
Untreated
• CR: 23%
• Not reported
c) Patients with relapsed/refractory AML
Fernandez et al.100 • Patients, n: 9
• Median age, years (range):
59 (40–83)
• AML type, primary, % 100
• Median BM blasts, % (range):
22 (7–73)
• Cytogenetics, normal/int/poor, n:
2/3/4
• Decitabine 20 mg/m2/day
for 5 days every 4–5 weeks
• Median cycles, n (range):
6 (1–12)
• CR: 56%
• PR: 22%
• PD: 22%
• Median TTP, months
(range): 11 (1–20)
• Median OS, months (range):
12 (10–20)
George et al.53 • Patients, n: 19
• Median age, years (range):
61 (22–78)
• All patients had intermediate or
poor risk cytogenetics
• >3 chemotherapy
regimens, %: 79%
• Post HCT, %: 21
• Decitabine 20 mg/m2/day
for 5 days
• Median cycles, n: 2
• No patients achieved
CR or CRi
• Discontinuation due
to disease
progression
or death, %: 95
• Median OS, months: 3.1
• Mortality at 30 days, n: 0
CR: complete response, DFS: disease free survival, HCT: hematopoietic stem cell transplantation, ORR: overall response rate, OS: overall
survival, PD: progressive disease, PR: partial response, SD: stable disease, and TTP: time to progression.
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Elderly Patients with AML
7.1. Achieving Complete Response
Irrespective of age, long-term survival of patients with AML
treated with IC depends on the ability to clear BM blasts at an
early stage and induce a CR.42,43 Similarly, in patients with AML
treated with LDAC, OS is strongly associated with achievement
of CR.8 By contrast, one of the observations regarding azacitidine
is its apparent ability to offer a survival advantage in elderly
patients with AML who achieve any kind of hematological
response, regardless ofwhetherCR is achieved.22,25 In apalliativesetting, the translation of any hematological response, not only
CR, into improved survival might establish a new paradigm in
the treatment of AML, especially in the elderly.
7.2. Maintenance or Post-Remission Therapy
Controversies exist regarding the role of post-remission chemo-
therapy in improving long-term survival in elderly patients with
AML. Several studies have indicated that subsequent cycles of
induction chemotherapy following achievement of CR offered
no benefit to patients. 3,44,45 By contrast, early clinical data
suggest that maintenance therapy with azacitidine may benefit
some patients with AML, MDS or chronic myelomonocytic
leukemia (CMML).46 In a phase II study, 23 patients with AML/
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received azacitidine as maintenance therapy; median duration
of CRwas 13.5 months. Of particular interestwas a subgroup of 4
patients with a karyotype including trisomy 8, who all achieved
CR with durations of 18–30.5 months. Furthermore, as with
MDS,47 evidence suggests that a proportion of AML patients who
respond to azacitidine go on to achieve a better response with
continued treatment.25 Also, it is likely that termination of
treatment with azacitidine following a response could lead to
rapid relapse as has recently been observed in patients with
MDS.48 Indeed, given the reversible nature of epigenetic modi-
fications, it is likely that continuous treatment with azacitidine
is required in patients with AML, though this assertion requires
substantiation in prospective clinical trials.
7.3. Relapsed or Refractory AML
There isnostandardof care for relapsed/refractoryAML following
chemotherapy. The prognosis is generally very poor.49,50
Several retrospective studies have assessed azacitidine in
this setting. Some studies have reported superior outcomes in
first-line versus relapsed/refractory patients. For example,
Maurillo et al. reported an overall response rate (ORR) of 48%
vs 19%, respectively, in the two groups (p = 0.006) which
translated into an OS of 9 months vs 7 months. 36 Other
studies have demonstrated similar outcomes in first-line
versus relapsed/refractory patients treated with azacitidine.51
Results from retrospective studies suggest that decitabine
may have limited clinical activity in patients with relapsed/
refractory AML. In a study of 47 patients treated with decitabine
in a salvage setting, only 4 patients achieved a CR.52 Similarly, in
a retrospective study of 19 patients with relapsed/refractory
AML, nopatients achievedCR/CRi andOSwasonly3.1 months.53
Whether the preclinical observation of cross resistance
between decitabine, but not azacitidine, and cytarabine is
clinicallymeaningful is not yet known.54 In general, the available
data suggest that HMA might only have limited activity in the
setting of relapsed/refractory AML after chemotherapy. Novel
salvage therapies within clinical trials are urgently required.
7.4. Allogeneic Hematopoietic Cell Transplant (HCT)
Allogeneic HCT is a potentially curative treatment for some
patients with AML.55 Following the introduction of RIC-HCT,
an increasing number of elderly patients is offered such a
treatment modality.56–61 Nevertheless, relapse remains an
issue.55 Several studies have shown azacitidine to benefit
patients in a post-allogeneic HCT setting as either a mainte-
nance 62–65 or a salvage64,66–70 therapy. Through an observed
expansion of regulatory T-cells, azacitidine might augment
the graft-versus-leukemia (GvL) effect without increasing the
risk of graft-versus-host disease (GVHD).71
7.5. Quality of Life and Tolerability Considerations
In a palliative setting, it is essential that a treatment is well
tolerated, feasible in an outpatient setting and maintains, or
improves, quality of life. Both azacitidine and decitabine have
similar safety profiles, which are comparable to that known
for LDAC.11,15,18 The most predominant grade 3/4 AEs arehematological toxicities that are generally manageable by dose
delays and/or supportive measures. Pleyer et al. found that the
majority of hematological toxicities with azacitidine were docu-
mented during early treatment cycles, as is the case in MDS.25,72
As expected, themost predominant non-hematological toxicities
were gastrointestinal events and injection site reactions. These
events were generally mild and managed with standard sup-
portive measures.
Furthermore, a recent retrospective analysis indicated that
azacitidine can induce transfusion independence in ~50% of
previously transfusion-dependent patients with AML.51 As
well as being a strong prognostic factor for prolonged survival,
transfusion independence is likely to improve quality of life.51
Generally, quality of life must be considered a key goal of
treatment. Unfortunately, there is a universal paucity in
research evaluating quality of life in both curative and non-
curative treatment options in elderly patients with AML. For
HMA, patient-reported outcomes were studied in patients
with MDS treated with azacitidine. Encouragingly, patients in
a phase III study experienced significantly improved quality of
life parameters (fatigue, dyspnea, physical functioning, posi-
tive affect and psychological distress) than patients receiving
BSC.73 Patient-reported outcomes and quality of life assess-
ments are an important endpoint in the AZA-AML-001 study.
Thus, these results will help define the exact impact of
azacitidine on the quality of life in elderly patients.8. Treatment Schedules of Hypomethylating
Agents in AML
It is accepted that the treatment schedule of a drug in a phase
III study provides guidance to practitioners in treating
patients when this agent is approved later. However, this
does not necessarily mean that the issue of dosing is finally
settled. For HMA, treatment approaches used in clinical trials
for patients with AML have largely been extrapolated from the
experience in MDS. This is particularly true for decitabine.
In the DACO-016 trial, decitabine was applied at a dose of
20 mg/m2/day for 5 days every 4 weeks,15 Yet, results from a
phase II trial with decitabine in elderly patients with AML
support the likelihood that a 10 day schedule, with subse-
quent cycles abbreviated based on response and toxicity could
be more effective than the 5 day regimen used in the
DACO-016 trial.19 This issue requires substantiation in pro-
spective clinical trials comparing the two regimens.9. Differences in Mechanism of Action Between
Azacitidine and Decitabine
Phase II data and retrospective studies hint that azacitidine
and decitabine may have different activities in some AML
populations e.g. WHO–AML (20–30%) and relapsed/refractory
AML. Mechanisms of action that might underlie possible
differences in clinical activities of azacitidine and decitabine
have not been defined; however, preclinical comparisons of
the two drugs suggest that they have different activities and
are non-equivalent agents.74
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is any correlation between the extent of hypomethylation
elicited by azacitidine and subsequent clinical response. The
evidence from our study 22 and others 75,76 indicate that changes
in methylation with azacitidine therapy do not correlate with
clinical response. We found that although treatment with
azacitidine rapidly reduced LINE-1 DNA methylation levels (a
surrogate of global methylation) within the first cycle, it was the
initial degree of methylation, rather than treatment-associated
changes, which was found to be indicative of subsequent
response.77 Similarly, reduction in the methylation at the
p15CDKN2B locus following azacitidine treatment did not correlate
with response in patients with MDS. 76 Conversely, a recent
phase I study assessing oral azacitidine in patients with MDS,78
indicated that extent of hypomethylation correlated with
response.
Currently, it is also unclear whether response to decitabine
correlates with changes in methylation. Some studies suggest
that early epigenetic changes predict clinical response in patients
with AML treated with decitabine. For example, Yang et al.
demonstrated that methylation levels of Alu repeats, LINE-1 and
total genomic DNAwere significantly decreased within 5 days of
treatment with decitabine in patients with AML; reduced
methylation correlated with response.79 Similarly, in a recent
study, decitabine-mediated hypomethylation of several
tumor-suppressor genes, including p15CDKN2B, correlated with
subsequent clinical responsewithin the first cycle of treatment.80
Overall, however, it is not yet clear whether decitabine and
azacitidine have different effects on DNA hypomethylation in
clinical studies which could reflect functional differences be-
tween the two agents.
A key difference between azacitidine and decitabine is
that the former, being a ribonucleoside, is incorporated into
both RNA and DNA; decitabine, on the other hand, is a
deoxyribonucleoside and is only incorporated into DNA.74 In
preclinical studies in mice, it was estimated that 80–90% ofG1
Interphase 
(comprising G1, S, G2)
Fig. 3 – Impact of azacitidine and decitabine on the cell cycle. Bo
However, it is thought that azacitidine is also incorporated into R
Adapted from Morgan DO. The cell cycle: principles of control. Nazacitidine becomes incorporated into RNA; the remaining
10–20% is incorporated into DNA.81 In human AML cell lines,
approximately 65% of azacitidine appears to incorporate into
RNA.74 Therefore, the conventional description of azacitidine
as a DNA hypomethylating agent may be an oversimplifica-
tion, overlooking potential additional mechanisms of activity
mediated via incorporation into newly synthesized RNA,
including ribosomal RNA (rRNA), transfer RNA (tRNA), mes-
senger RNA (mRNA) andmicroRNAs. Studies performed in the
1970s and 1980s demonstrated that azacitidine may alter the
processing of tRNAs and rRNAs, leading to inhibition of
protein synthesis.82–84 However, this is a largely understudied
area of research. Nevertheless, possibly due to dual effects on
DNA hypomethylation and protein synthesis, azacitidine
appears to have multiple effects on cells.74,85,86 In fact,
previous studies have indicated that azacitidine rapidly
(within 4–8 h) elicits cell death in AML cell lines, and this
predominantly occurs during the G-1 phase of the cell cycle
(when cells are not actively dividing).87,88 These observations
indicate that the cytotoxic effects of azacitidine are not
restricted to actively dividing cells (S phase) and, therefore,
may be related to RNA-mediated mechanisms. Decitabine
also leads to cell cycle arrest and cell death.74 However,
incorporation of decitabine into DNA is restricted to cells in
S-phase (Fig. 3). Azacitidine's potential to kill cells indepen-
dently of the cell cycle may be important because only a
proportion of hematopoietic stem cells in the BM are actively
dividing at any given time.47 Furthermore, RNA-mediated
effects on cell viability may occur more rapidly than
DNA-mediated effects, which require cell division for passive
reduction of DNA methylation to occur. For example,
azacitidine-mediated inhibition of protein synthesis in vitro
occurred within 24 h in human AML cell lines (which is within
the doubling time of these cells).74 These rapid changes could
potentially explain the rapid anti-leukemia activity of
azacitidine that has been observed in some trials. 11,22S
G2
M
Azacitidine
Decitabine
th incorporate into replicating DNA during the S phase.
NA which can occur at any stage of the cell cycle.
ew Science Press, Sunderland, MA; 2007.
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such as p15INK4b, takes up to 72 h in culture.89 Another
difference between azacitidine and decitabine is that azacitidine
has a greater effect on global gene expression.74 At thispoint, it is
worth mentioning that several caveats remain to be considered
in interpreting these results. The sometimes conflicting data
might reflect differences in treatment schedules, loci assessed,
the techniques used to quantify methylation and time-points at
which samples were taken in relation to treatment. The target
cells under investigation represent a further critical point. Most
of the studies were conducted on relatively heterogeneous
populations of blood or bone marrow cells. Thus, dynamic
methylation changes under treatment with HMA at a cellular
level could not be distinguished from those occurring at the
population level as a result of selective death of cells with a
particularly high or low level of methylation.
Finally, the effects of HMA on cell viability cannot be
accounted for solely by epigenetic mechanisms. Evidence
suggests that a dose-dependent mechanism of action for both
HMA exist. The hypomethylation-mediated effect on gene
re-expression is demonstrated at low doses while inhibition
of cell proliferation (decitabine) and cytotoxicity (azacitidine)
is observed at high doses.74
Currently, there is no direct clinical evidence to confirm
whether differences in mechanism of action translate into
differences in clinical activity. This could only be addressed by
translational studies and head-to-head prospective trials.
However, as the RNA-mediated effects of azacitidine are
beginning to be unraveled, specific molecular pathways that
underlie possible differences between the two drugs in the
clinic are being identified. For example, recent work has
demonstrated that azacitidine reduces levels of ribonuclease
reductase (RR), a rate-limiting enzyme in DNA synthesis.
Although not fully understood, it is thought that this
phenomenon may be the result of azacitidine destabilizing
the mRNA of one the of RR's subunits. It is possible that this
mechanism underlies the activity of the azacitidine in
patients with AML. 90 Characterization of differences in the
mechanism of action of azacitidine and decitabine at the
molecular level may, ultimately, guide treatment decisions in
individual patients.10. Summary and Future Perspectives
Given that the incidence of AML (and indeed secondary AML)
increases with age,91 most patients are deemed unsuitable
for, or decline, intensive treatment options,7 and outcomes
following intensive treatment are poor,6 there is a major
unmet medical need for well-tolerated treatment options that
can improve survival and quality of life in elderly patients
with AML.
Owing to their acceptable tolerability profiles, and emerg-
ing evidence of clinical efficacy, HMAmay provide an exciting
new approach to the treatment of elderly patients, either as
monotherapy or in combination regimens with other agents/
approaches including histone deacetylase inhibitors, immu-
nomodulatory drugs like lenalidomide, cytotoxics or alloge-
neic HCT. In the European Union (EU), the recent approval of
decitabine for the treatment of elderly patients (≥65 years old)with AML will certainly provide a much needed treatment
option for patients who are not candidates for IC. However, the
phase III DACO-016 data need to be interpreted with caution,
given that the trial did not achieve its primary endpoint and it
was not designed as a non-inferiority trial. On the other hand,
concerns regarding the efficacy of decitabine are, in part,
mitigated by its favorable tolerability profile and the dearth of
other treatment options in this setting.
Clinical evidence demonstrates that azacitidine has prom-
ising activity in patients with AML. It is already licensed for
patients with 20–30% blasts (for whom it confers a survival
benefit) 11 and phase II data/retrospective studies suggest that
it is active and well tolerated in patients with >30% BM
blasts,22 including those with relapsed/refractory AML.22,41,51
Furthermore, azacitidine appears to prolong survival in
patients with AML without the achievement of CR.22 Owing
to these findings, data from the AZA-AML-001 trial are eagerly
awaited to define the role of azacitidine in the treatment of
AML in the elderly.
How does the accumulating evidence of the clinical activity
of HMA change the treatment landscape for elderly patients
with AML? Indeed, these developments do not render intensive
treatment options obsolete. The previously discussed survival
data and limitations of HMA must be considered carefully (the
DACO-016 studydid notmeet its primary end point of improved
survival with decitabine and the results of the phase III
AZA-AML-001 trial are yet unavailable).
Thus, wherever possible, both curative and non-curative
treatment options should be offered within clinical trials. If
this is not feasible, patients and care-givers need to be made
absolutely clear of the risk–benefit profiles of (where applica-
ble) IC, LDAC, HCT and HMA. Evidence suggests that elderly
patients often confuse curative and non-curative approaches,
highlighting the need for thorough counseling between
physician and patient, so that the latter can make an
informed choice on their preferable approach. 9
Therefore, before embarking on a HMA-based treatment
regimen, it is essential that goals of therapy are clearly
elucidated. Both patient- and disease-related prognostic
factors that may indicate, or preclude, IC or LDAC such as
age, comorbidity burden, PS, cytogenetics and likelihood of CR
need to be considered in decision making.8,32–35 Furthermore,
recent developments suggest that molecular profiling of
aberrations such as NPM1 and DNMT3A mutations, and MLL
translocations, could identify patients who are most likely to
benefit from a certain treatment or dose intensity.92–94 Our
approach is to discuss in depth with the patients the
possibilities available. We suggest a curative treatment option
(IC and/or HCT) in patients with no contraindications or a
non-curative approach within a trial. If clinical studies are
not feasible and based on our experience, we recommend
azacitidine in patients with BM blasts 20–30%. If blasts
are >30%, we advice either LDAC or decitabine based on
cytogenetics. We must reiterate that there are no direct
head-to-head data available at the moment to make objective
comparisons between azacitidine and decitabine. Neverthe-
less, it may well be that further molecular and translational
studies, aimed at fully understanding the mechanism of
action of the two drugs, could drive treatment choices in
specific subgroups of patients.
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IC are not necessarily mutually exclusive. Indeed, in vitro
data suggest a possible synergistic effect of cytarabine and
azacitidine when azacitidine is administered before cyta-
rabine probably through the induction of deoxycytidine
kinase by azacitidine which phosphorylates cytarabine to its
active compound, ara-CTP.95,96 Yet, clinical data to the safety,
efficacy, and optimal scheduling of HMA and chemotherapy
in acute leukemias are very limited. In 17 pediatric patients
with relapsed acute lymphoblastic leukemia after high-dose
cytarabine, treatment with azacitidine followed by another
course of high-dose cytarabine yielded a complete remission
in two of 9 evaluable patients in a phase I-study. 97
Recently, a pilot trial in elderly patients with newly
diagnosed AML which assessed the safety of azacitidine
added to standard induction and consolidation therapy
was published. The authors concluded that the combina-
tion of azacitidine 75 mg/m2 with standard induction
therapy was feasible and this combination selected as an
investigational arm in a randomized phase-II study, which
is currently halted due to an increased cardiac toxicity in
the experimental arm.98 Another clinical trial is evaluating
an initial priming with azacitidine and a sequential,
response-adapted application of induction chemothe-
rapy in elderly patients with AML (DRKS00004519). Thus,
integrating both options in well-designed trials might
further optimize outcome even in younger patients.
In summary, there is strong preclinical rationale, and
clinical data, to support the use of HMA in elderly patients
with AML. The AZA-AML-001 trial will be instrumental in
indicating azacitidine's role in this setting and will determine
whether it can provide an additional option to decitabine in
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